Mild cognitive impairment (MCI) can be an early indicator of Alzheimer's disease or dementia, so identifying those with cognitive issues early could lead to interventions and better outcomes.

Mild cognitive impairment (MCI) can be an early indicator of Alzheimer's disease or dementia, so identifying those with ...

A new interactive tool from AHRQ allows researchers, policymakers and others to explore trends in hospital care for sepsis, a life-threatening condition that is among the most expensive to treat in U.

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

Cognitive Decline Market The global cognitive decline market is projected to grow at a CAGR of 5.8%, attaining a value of USD 3.8 Bn by 203 ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The inflation rate in Germany is expected to be +2.3% in February 2025. It is measured as the change in the consumer price index (CPI) compared with the same month a year earlier. Based on the results ...

Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

A modeling study predicts a substantial rise in MASLD prevalence and associated liver-related complications in the United States in the coming years, posing a significant challenge to health systems.